InvestorsHub Logo
Followers 65
Posts 23970
Boards Moderated 0
Alias Born 11/23/2016

Re: Hoskuld post# 428586

Saturday, 08/26/2023 7:54:06 PM

Saturday, August 26, 2023 7:54:06 PM

Post# of 463457
Anavex would not announce plans to initiate a confirmatory AD trial if the P2b/3 trial was pivotal.

Anavex Life Sciences Reports Fiscal 2023 Second Quarter Financial Results

Alzheimer’s disease: Full data ANAVEX®2-73-AD-004, including newly available preliminary results of surrogate biomarkers of pivotal Phase 2b/3 clinical trial. The Company intends to discuss these findings with regulatory authorities in the context of the ongoing clinical development of ANAVEX®2-73 in this indication, with the goal of providing a much-needed treatment to the millions of patients living with Alzheimer’s disease with a convenient once-daily oral treatment. The Company plans to proceed in parallel with the initiation of a confirmatory Alzheimer’s disease study.


Here parallel refers to the preliminary surrogate biomarkers and considering initiating discussions with regulatory agencies for Accelerated Approval. Ergo the P2b/3 trial was not a pivotal registrational P3 trial.

With newly available preliminary efficacy results of surrogate biomarkers, we consider initiating discussions with regulatory agencies for Accelerated Approval Pathway for ANAVEX®2-73 (blarcamesine),” said Christopher U Missling, PhD, President and Chief Executive Officer of Anavex.


Definitions should NOT be ignored!

It shouldn't be too difficult for experienced biotech investors to understand the context and correct conclusions.

The longer we wait, the sooner we will get rich!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News